Sarah T.
- Country
- France
- Department
- Allergologie Pédiatrique
Research Overview
- A Phase 3, Double-blind, Placebo-controlled, Randomized Study to Assess the Efficacy and Safety of Epicutaneous Immunotherapy with DBV712 250 μg in 4-7-year-old Children with Peanut Allergy (VITESSE)
- A Phase 3, Double-Blind, Placebo-Controlled, Randomized Study to Assess the Safety of Epicutaneous Immunotherapy with DBV712 250 µg in 1-through 3-year-old Children with Peanut Allergy
Data & Insights
Has run more than one trial at 5 of 20 partner sites.
Specializations
Allergy Research
Specializes in investigating innovative therapeutic approaches for peanut allergy management, particularly focusing on pediatric populations aged 4-7 years.
- Food Allergy Immunotherapy
- Pediatric Allergy Treatment
- Desensitization Protocols
Concentrates on evaluating novel immunotherapy treatments designed to improve safety and efficacy in food allergy management.
Pediatric Medicine
Dedicated to advancing pediatric allergology through research into simplified treatment approaches for young children with severe food allergies.
- Child-Focused Treatment Protocols
- Safety Assessment in Children
- Age-Specific Therapeutic Approaches
Explores treatment methodologies specifically tailored for early childhood intervention in allergy management.
Therapeutic Innovation
Investigates cutting-edge desensitization techniques and their implementation in clinical practice for food allergy treatment.
- Novel Treatment Delivery Systems
- Long-term Efficacy Studies
- Clinical Safety Protocols
Focuses on developing and evaluating simplified therapeutic approaches for allergic conditions in pediatric patients.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.